Unlocking the biology of RAGE in diabetic microvascular complications

Trends Endocrinol Metab. 2014 Jan;25(1):15-22. doi: 10.1016/j.tem.2013.08.002. Epub 2013 Sep 3.

Abstract

The discovery of the receptor for advanced glycation end-products (RAGE) set the stage for the elucidation of important mechanisms underpinning diabetic complications. RAGE transduces the signals of advanced glycation end-products (AGEs), proinflammatory S100/calgranulins, and high mobility group box 1 (HMGB1), and is a one of a family of receptors for lysophosphatidic acid (LPA). These ligand tales weave a theme of vascular perturbation and inflammation linked to the pathogenesis of the chronic complications of diabetes. Once deemed implausible, this concept of inflammatory cues participating in diabetic complications is now supported by a plethora of experimental evidence in the macro- and microvasculature. We review the biology of ligand-RAGE signal transduction and its roles in diabetic microvascular complications, from animal models to human subjects.

Keywords: complications; diabetes; inflammation; ligands; receptor for AGE.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Carrier Proteins / physiology
  • Diabetes Complications / physiopathology*
  • Diabetic Angiopathies / physiopathology
  • Diabetic Nephropathies / physiopathology
  • Diabetic Retinopathy / physiopathology
  • Formins
  • Glycation End Products, Advanced / metabolism*
  • HMGB1 Protein / metabolism
  • Humans
  • Hyperglycemia / complications
  • Inflammation / physiopathology*
  • Kidney / metabolism
  • Leukocyte L1 Antigen Complex / metabolism
  • Ligands
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / physiology*
  • Signal Transduction / physiology

Substances

  • Carrier Proteins
  • Diap1 protein, mouse
  • Formins
  • Glycation End Products, Advanced
  • HMGB1 Protein
  • Leukocyte L1 Antigen Complex
  • Ligands
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic